Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies.
Combining chemotherapy with immunotherapy may improve survival in some patients with microsatellite stable metastatic colorectal cancer, but the benefits may vary based on individual patient characteristics.
Where it sits
this study against the rest of the b7-33 (relaxin) corpusSummary and findings
This study analyzed data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors for metastatic microsatellite stable colorectal cancer. A total of 130 patients were included, with 38 receiving chemotherapy alone and 92 receiving chemoimmunotherapy. The median overall survival was significantly improved in the chemoimmunotherapy group compared to chemotherapy alone.
Abstract
<h4>Background</h4>Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1. However, emerging evidence suggests that chemotherapies may overcome this resistance when combined with immunotherapy.<h4>Methods</h4>We conducted a pooled analysis of individual patient data from two phase II trials evaluating oxaliplatin-based chemotherapy combined with checkpoint inhibitors as first-line treatment for MSS metastatic colorectal cancer. The MEDITREME trial is a single-arm study assessing durvalumab and tremelimumab with oxaliplatin-based chemotherapy, while the METIMMOX trial is a randomized study comparing standard oxaliplatin-based chemotherapy with an alternating regimen of oxaliplatin-based chemotherapy and nivolumab. We compared overall survival (OS), progression-free survival (PFS), and response rates between patients treated with chemotherapy alone <i>versus</i> chemoimmunotherapy, and evaluated the association between these outcomes and transcriptomic and immunoscore data.<h4>Results</h4>A total of 130 patients were included: 38 who received chemotherapy alone and 92 chemoimmunotherapy. The median OS was significantly improved in the chemoimmunotherapy group compared with chemotherapy alone (not reached <i>vs</i>. 15.3 months; HR = 0.58; 95% CI, 0.36-0.96; <i>p</i> = 0.03). The complete response rates were higher with chemoimmunotherapy (14% <i>vs</i>. 5%). No significant differences were observed in PFS. High baseline CD8<sup>+</sup> T-cell infiltration was associated with improved outcomes in patients receiving chemoimmunotherapy but not in those treated with chemotherapy alone.<h4>Conclusions</h4>This pooled analysis provides compelling evidence supporting the clinical benefit of first-line chemoimmunotherapy in a subset of patients with MSS mCRC. Baseline CD8<sup>+</sup> T-cell infiltration may serve as a predictive biomarker for identifying patients most likely to benefit from this treatment approach.
Background
This paper addresses the challenge of treating colorectal cancer with microsatellite stable (MSS) status, which is resistant to immune checkpoint inhibitors. Prior studies have indicated that combining chemotherapy with immunotherapy may enhance treatment efficacy in this context. Understanding the outcomes of such combinations is crucial for improving treatment strategies for MSS metastatic colorectal cancer.
Methods
The study conducted a pooled analysis of individual patient data from two phase II trials: the single-arm MEDITREME trial and the randomized METIMMOX trial. A total of 130 patients were included, with 38 receiving chemotherapy alone and 92 receiving chemoimmunotherapy. The primary outcomes measured were overall survival (OS), progression-free survival (PFS), and response rates.
Results
The median overall survival was significantly improved in the chemoimmunotherapy group compared to chemotherapy alone, with a median OS not reached versus 15.3 months; HR=0.58; 95% CI, 0.36-0.96; p=0.03. The complete response rates were 14% for chemoimmunotherapy compared to 5% for chemotherapy alone. No significant differences were observed in progression-free survival.
Interpretation
The findings suggest that combining chemotherapy with immunotherapy may provide a survival advantage for patients with MSS metastatic colorectal cancer, particularly in those with high baseline CD8+ T-cell infiltration. However, the effect size, while statistically significant, may not be clinically meaningful for all patients. Limitations include the small sample size and potential biases from the pooled analysis, which could affect the generalizability of the results.
Key findings
- Median OS not reached vs 15.3 months; HR=0.58; 95% CI, 0.36-0.96; p=0.03.
- Complete response rates were higher with chemoimmunotherapy (14% vs 5%).
- No significant differences in progression-free survival.
Limitations
- Small sample size of n=130.
- Pooled analysis may introduce biases.
- No significant differences in progression-free survival.
- Follow-up duration for some outcomes not specified.